EZH2 and cancer: For instance, targeting of EZH2, the catalytic subunit of the PRC2, is currently under evaluation in several phase 1/2 clinical trials (76) and therefore could potentially offer previously unknown epigenetic therapeutic options for RBNSig-high cancers with EZH2 dysregulation.